Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality7/10

FDA clears CELZ-201 ADAPT expansion; Phase 3 path under consideration

Jun 22, 2026, 9:17 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Expansion clearance and rapid enrollment reduce clinical and regulatory risk, improving probability of Phase 3 success; near-term catalysts could lift sentiment and valuation, though meaningful upside hinges on subsequent data readouts.

AI summary

What happened, with direct paths to the underlying reporting

FDA-cleared expansion of CELZ-201's ADAPT trial adds a 15-patient cohort focused on lower opioid use, with >85% enrollment and summer 2026 completion. The trial's AI-based PRO data collection and positive interim 180-day results underpin Phase 3 discussions and a broader chronic lower back pain indication, potentially expanding CELZ's market and future value.

FDA clears expansion of CELZ-201 ADAPT trial; 15-patient cohort enrolled.
Expansion >85% enrolled; finish by summer 2026 with AI monitoring.
180-day data showed meaningful ODI% and pain improvements with strong safety.
Phase 3 discussions with FDA planned using expanded dataset.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.